189763-57-3

Usage

Type of compound

Ketone derivative

Structural features

a. Fluoro-substituted phenyl ring
b. Piperazine moiety

Potential applications

a. Pharmaceutical industry
b. Development of new drugs with central nervous system activity

Use in organic synthesis

Building block

Safety precautions

Handle and use with caution in a controlled laboratory setting due to potential physiological effects and chemical reactivity.

Upstream product

• 455-86-7 3,4-Difluorobenzoic acid 
• 188345-25-7 3,4-difluoro-N-methoxy-N-methylbenzamide 
• 110-85-0 piperazine 
• 369-33-5 3',4'-difluoroacetophenone 

Downstream Products

• 847969-41-9 1-[3-fluoro-4-(4-{[5-(methylsulfonyl)-2-(1-piperidinyl)phenyl]carbonyl}-1-piperazinyl)phenyl]ethanone 
• 847546-84-3 1-[3-fluoro-4-(4-{[4-(methylsulfonyl)-2-biphenylyl]carbonyl}-1-piperazinyl)phenyl]ethanone 
• 847546-83-2 1-[3-fluoro-4-(4-{[4'-fluoro-4-(methylsulfonyl)-2-biphenylyl]carbonyl}-1-piperazinyl)phenyl]ethanone 
• 927096-90-0 C₁₉H₁₈FN₃O₄ 
• 847545-68-0 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-1-carbonyl]-4-chloro-N-methyl-benzenesulfonamide 
• 847545-67-9 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-1-carbonyl]-4-chloro-benzenesulfonamide 
• 330636-53-8 1-{3-fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-1-yl]-phenyl}-ethanone 
• 1079817-08-5 C₂₆H₂₄F₂N₂O₄S 
• 1147093-90-0 C₂₆H₂₄ClFN₂O₄S 
• 1147093-89-7 C₂₂H₂₄ClFN₂O₄S 
• 1079816-94-6 C₂₄H₂₅F₄N₃O₃ 
• 847972-17-2 1-{4-[4-(5-bromo-2-morpholin-4-yl-benzoyl)-piperazin-1-yl]-3-fluoro-phenyl}-ethanone 
• 1079816-93-5 C₂₄H₂₈FN₃O₃ 
• 310415-30-6 1-{4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-1-yl]-3-fluoro-phenyl}-ethanone 

Relevant academic research and scientific papers

The pollen tube growth regulator (by machine translation)

The pollen tube growth regulating agent [a]. (1) A compound represented by the general formula [a], a salt thereof, a solvate thereof selected from the group consisting of at least 1 kind, the pollen tube growth regulator. [Drawing] no (by machine translation)

2-Substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-oxy-5-methylsulfonyl pyridine piperazine acidamide analogue with

Sulfanyl substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, R3, X, X1, and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS

The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS

The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.